synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
== Research == The minimum dose (5 mg/kg) was confirmed in a clinical trial performed by HTI Bio-services, Inc. It evaluated the effective dose for the treatment of an infected dermal wound. The study included forty-eight mixed breed dogs (both male and female) with weights ranging from 14.5-24.5 kilograms. These dogs were randomly placed into treatment groups. Once wounds were created, the dogs were inoculated with culture both containing both Escherichia coli and Klebsiella pneumoniae. Pertinent observations and measurements were then taken and tabulated. Culture scores were significantly reduced, confirming 5 mg/kg to be an effective dose. Clinical field trials were also performed to evaluate both the efficacy and safety of difloxacin tablets. Clinical signs of bacterial infections were defined in a protocol. Dogs who presented to investigators with these signs were admitted into the study. In total, eighteen veterinarians located in four different geographical areas of the U.S. (Southeast, Midwest, Northwest, and West) conducted these clinical efficacy and safety evaluations.
Osborne's ligament, also Osborne's band, Osborne's fascia, Osborne's arcade, arcuate ligament of Osborne, or the cubital tunnel retinaculum, refers to either the connective tissue which spans the humeral and ulnar heads of the flexor carpi ulnaris (FCU) or another distinct tissue located between the olecranon process of the ulna and the medial epicondyle of the humerus. It is named after Geoffrey Vaughan Osborne, a British orthopedic surgeon, who described the eponymous tissue in 1957.
==== Sweden ==== In 2008, an 18-year-old Swedish woman died in Stockholm after taking mephedrone. The newspaper Svenska Dagbladet reported the woman went into convulsions and turned blue in the face. Doctors reported she was comatose and suffering from hyponatremia and severe hypokalemia; the woman died one and a half days after the onset of symptoms. An autopsy showed severe brain swelling. Mephedrone was scheduled to be classified as a "dangerous substance" in Sweden even before the woman's death at Karolinska University Hospital on 14 December, but the death brought more media attention to the drug. The possession of mephedrone became classified as a criminal offence in Sweden on 15 December 2008.
== Occurrence == Protactinium is one of the rarest and most expensive naturally occurring elements. It is found in the form of two isotopes, 231Pa and 234Pa, with the isotope 234Pa occurring in two different energy states. Nearly all natural protactinium is 231Pa. It is an alpha emitter and is formed by the decay of uranium-235, whereas the beta-radiating 234Pa is produced as a result of uranium-238 decay. Nearly all uranium-238 (99.8%) decays first to the shorter-lived 234mPa isomer. Protactinium occurs in uraninite (pitchblende) at concentrations of about 0.3–3 parts 231Pa per million parts (ppm) of ore. Whereas the usual content is closer to 0.3 ppm (e.g. in Jáchymov, Czech Republic), some ores from the Democratic Republic of the Congo have about 3 ppm. Protactinium is homogeneously dispersed in most natural materials and in water, but at much lower concentrations on the order of one part per trillion, corresponding to a radioactivity of 0.1 picocuries (pCi)/g. There is about 500 times more protactinium in sandy soil particles than in water, even when compared to water present in the same sample of soil. Much higher ratios of 2,000 and above are measured in loam soils and clays, such as bentonite.
Sources: en.wikipedia.org
=== Founding === National Semiconductor was founded in Danbury, Connecticut, by Dr. Bernard J. Rothlein on May 27, 1959, when he and seven colleagues, Edward N. Clarke, Joseph J. Gruber, Milton Schneider, Robert L. Hopkins, Robert L. Koch, Richard R. Rau and Arthur V. Siefert, left their employment at the semiconductor division of Sperry Rand Corporation. The founding of the new company was followed by Sperry Rand filing a lawsuit against National Semiconductor for patent infringement. By 1965, as it was reaching the courts, the preliminaries of the lawsuit had caused the stock value of National to be depressed. The depressed stock values allowed Peter J Sprague to invest heavily in the company with Sprague's family funds. Sprague also relied on further financial backing from a pair of West Coast investment firms and a New York underwriter to take control as the chairman of National Semiconductor. At that time Sprague was 27 years old. Jeffrey S. Young characterized the era as the beginning of venture capitalism. That same year National Semiconductor acquired Molectro. Molectro was founded in 1962 in Santa Clara, California, by J. Nall and D. Spittlehouse, who were formerly employed at Fairchild Semiconductor. The acquisition brought in two experts in linear semiconductor technologies, Robert Widlar and Dave Talbert, who were also formerly employed at Fairchild. The acquisition of Molectro provided National with the technology to launch itself in the fabrication and manufacture of monolithic integrated circuits.
==== William Henry Perkin’s mauveine ==== In 1856, 18 year old William Perkin accidentally discovered a dye he called mauve while trying to make quinine from the oxidation of allyl toluene in his home lab for his academic advisor and boss August Wilhelm von Hoffman. Hoffman reportedly referred to aniline, a major step in the synthesis, as his "first love," and was excited to have Perkin working with it. Perkin communicated with the textile industry, including Pullars of Perth, and John Hyde Christie, the chemist and general manager of John Orr Ewing and Co. about how to best market and produce his dye. He started production of aniline purple near London at the end of 1857 and remained the only producer for at least a few months. Perkin began making the intermediates for his dyes in-house, for example, nitro-benzene, expanding the scale of operations. By the summer of 1859, according to a satirical magazine Punch, London had fallen ill with 'the mauve measles'.
Grammostola mechanotoxin #4 (GsMTx-4, GsMTx4, GsMTx-IV), also known as M-theraphotoxin-Gr1a (M-TRTX-Gr1a), is a neurotoxin isolated from the venom of the spider Chilean rose tarantula Grammostola spatulate (or Grammostola rosea). This amphiphilic peptide, which consists of 35 amino acids, belongs to the inhibitory cysteine knot (ICK) peptide family. It reduces mechanical sensation by inhibiting mechanosensitive channels (MSCs). GsMTx-4 also serves as a cationic antimicrobial peptide against Gram-positive bacteria.
Sources: en.wikipedia.org
Paul Leonard-Morgan wrote the film's industrial music score. Leonard-Morgan created music to suit the film's futuristic setting. He experimented with band-based music, but decided it sounded over-produced and too safe. He turned to electronic music and used 1980s-style synthesisers and modern sound modules to create various combinations and applied distortion and other effects to the result. Leonard-Morgan said, "I was looking to create a timeless score which couldn't be placed in any particular era. So it's ended up being a cross between a modern dance track and evocative soundscapes." For scenes conveying the effect of the Slo-Mo narcotic, he composed new music with real instruments and then slowed the songs down to match the visuals, such that one second of his composed score could last ten minutes (slowed to 0.17% of original). He then added additional real-time score to the slowed track. An unofficially altered Justin Bieber song served as inspiration for the Slo-Mo theme. Garland said that Portishead instrumentalist Geoff Barrow "sent me a link to a Justin Bieber song slowed down 800 times and it became this stunning trippy choral music." Morgan recreated the effect based on the modified track, which was used in the finished film. The film used Bieber's music as a temporary placeholder during editing before the score was finalised. The film also features songs by artists including: "Poison Lips" by Vitalic; "Dubstride" by Yann McCullough and Gemma Kicks; "Snuffbox" by Matt Berry; "Pontiac Moon" by Robert J.
NPU terminology (NPU; Nomenclature for Properties and Units) is a patient-centered clinical laboratory terminology for use in the clinical laboratory sciences. Its function is to enable results of clinical laboratory examinations to be used safely across technology, time and geography. To achieve this, the NPU terminology supplies:
=== Acid derivatives === The formation of amide is promoted by CDI. Although the reactivity of CDI is less than acid chlorides, it is more easily handled and avoids the use of thionyl chloride in acid chloride formation, which can cause side reactions. An early application of this type of reaction was noted in the formation of peptide bonds (with CO2 formation as a driving force). The proposed mechanism for the reaction between a carboxylic acid and CDI is presented below.
Fish can also be made into floss (魚鬆; yú sōng), though initial stewing is not required due to the low collagen and elastin content of fish meat. Rabbit and duck floss can also be found in China. In Muslim-majority Indonesia and Malaysia, beef or chicken floss is the most popular variant, commonly called abon in Indonesian and serunding (also spelled serondeng) in Malay. In Malaysia, serunding is often served during Ramadan and Eid. In Nigeria, beef, goat or other meats are processed into a similar meat floss called dambu nama.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.